Myasthenia gravis treatment refers to the process of providing health care services by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease-causing fatigue and weakness in the skeletal muscles.
Sizing and Forecast
The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, emergence of plasma exchange, patient advocacy.
The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, long-term safety monitoring.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report
Segmentation & Regional Insights
The myasthenia gravis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses
North America was the largest region in the myasthenia gravis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp
Major Driver Impacting Market Growth
The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care services and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2022, according to the data published by the National Organization for Rare Disorders, a US-based non-profit organization providing support for individuals with rare diseases, autoimmune myasthenia gravis had an estimated prevalence of 14–40 per 100,000 individuals in the United States. For instance, in December 2021, according to the study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia, the global prevalence of myasthenia gravis was estimated to be 12.4 people per 100,000 people. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment market.
Key Industry Players
Major companies operating in the myasthenia gravis treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Avadel Pharmaceuticals plc, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., Zenyaku Kogyo Co. Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics
The myasthenia gravis treatment market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The medical terminology software global market report 2024 from The Business Research Company provides comprehensive…
The apples global market report 2024 from The Business Research Company provides comprehensive market statistics,…
The ip video surveillance and vsaas global market report 2024 from The Business Research Company…
The change and configuration management global market report 2024 from The Business Research Company provides…
The generative ai in gaming global market report 2024 from The Business Research Company provides…
The electric blankets global market report 2024 from The Business Research Company provides comprehensive market…